Latest news
Mathieu Schué joins CILcare as Project Director of Drug Development and Translational Research
Montpellier, January 14th, 2021: CILcare, the world leading CRO specialized in the field of Hearing, recently had the immense pleasure of welcoming Dr. Mathieu Schué to the team as Project Director of Drug Development & Translational Research. In this role,...
CILcare receives grant from the Occitanie Region to conduct research into potential ototoxic effects of investigated drugs for Covid-19
Montpellier, January 5th, 2021: CILcare, the world-leading CRO specialized in auditory research, is announcing the launch of its COVIDOTOTOX research project. Subsidized by the Occitanie Region at 87k€, the COVIDOTOTOX project aims to assess the potential side effects...
Video: HEARING MATTERS – What Can You Do To Prevent Ototoxicity ? CILcare/CBSET
What can you do to prevent drug-induced hearing loss, also known as ototoxicity ? In this video, CILcare and CBSET go into details about this important topic to see what could be done to improve the patients' lives. Get in touch with CILcare and CBSET to learn more...

Pharma / Biotech
Develop new therapies. Repurpose existing drugs in otology.

Medtech
Innovate with drug delivery devices for the inner ear. Speed up market access of hearing aids.

Nutraceutical
Develop health food ingredients for the prevention of hearing loss, tinnitus, or otitis.

Veterinary
Improve and develop products to treat ear inflammation in pets.
CILcare, the world leading CRO dedicating to ear disorders
CILcare is a unique CRO specialized in ear disorders. We offer preclinical services and consultancy to accelerate the development of innovative products for hearing loss, tinnitus, and otic disorders.
Because research & development in hearing is as fascinating as it is complex, preclinical studies require perfectly accurate and reproducible measures using state-of-the-art technology in acoustics and electrophysiology. CILcare’s core values lie in our validated and highly robust animal models, enabling us to deliver consistent and valid results.
Drawing from an extensive industrial background, we guide our partners from target identification to IND, and work closely together to advance auditory research and reach a common goal: serve patient population who need our help the most.
CILcare proposes services to develop innovative solutions for hearing loss, tinnitus, otitis, and ototoxicity

Drugs to treat Hearing Loss and Tinnitus

Drugs and Medical Devices to treat Otitis

Medications safe for the ear (absence of ototoxicity)

Regenerative Therapies: Gene and Cell Therapies

Implantable Drug Delivery Devices and Imaging
Hearing disorders: a high unmet medical need
young people at risk of hearing loss
Disabling hearing loss could affect nearly 1 billion people globally by 2050 according to the WHO. In 2013, 366 million people were affected. This alarming and rapidly growing prevalence mainly results from population growth and aging, modern lifestyles with excessive noise exposure, the intake of ototoxic drugs, and chronic ear infections.
Hearing loss has been ranked as the fourth highest cause of disability worldwide, higher than many other chronic diseases including diabetes, dementia, and chronic obstructive pulmonary disease. Deafness profoundly affects the quality of life of patients and is strongly linked to cognitive decline in the elderly. Unaddressed hearing loss costs countries an estimated US$ 750 billion annually, therefore posing a significant issue to our health systems.
A hundred pharmaceutical and biotechnology companies and thousands of academics are contributing to scientific progress in the auditory field. Although no drugs have been approved by authorities to treat hearing loss and tinnitus yet, some actors are reporting promising scientific research results. These hold the promise of filling an unmet medical need and having transformative impacts on patient populations in the near future.